241 related articles for article (PubMed ID: 26615563)
1. Nucleolin overexpression is associated with an unfavorable outcome for ependymoma: a multifactorial analysis of 176 patients.
Chen C; Chen L; Yao Y; Qin Z; Chen H
J Neurooncol; 2016 Mar; 127(1):43-52. PubMed ID: 26615563
[TBL] [Abstract][Full Text] [Related]
2. Altered MicroRNA Expression Is Associated with Tumor Grade, Molecular Background and Outcome in Childhood Infratentorial Ependymoma.
Zakrzewska M; Fendler W; Zakrzewski K; Sikorska B; Grajkowska W; Dembowska-Bagińska B; Filipek I; Stefańczyk Ł; Liberski PP
PLoS One; 2016; 11(7):e0158464. PubMed ID: 27390862
[TBL] [Abstract][Full Text] [Related]
3. Multifactorial analysis of predictors of outcome in pediatric intracranial ependymoma.
Ridley L; Rahman R; Brundler MA; Ellison D; Lowe J; Robson K; Prebble E; Luckett I; Gilbertson RJ; Parkes S; Rand V; Coyle B; Grundy RG;
Neuro Oncol; 2008 Oct; 10(5):675-89. PubMed ID: 18701711
[TBL] [Abstract][Full Text] [Related]
4. Prognostic marker analysis in pediatric intracranial ependymomas.
McLendon RE; Lipp E; Satterfield D; Ehinger M; Austin A; Fleming D; Perkinson K; Lefaivre M; Zagzag D; Wiener B; Gururangan S; Fuchs H; Friedman HS; Herndon JE; Healy P
J Neurooncol; 2015 Apr; 122(2):255-61. PubMed ID: 25563815
[TBL] [Abstract][Full Text] [Related]
5. Chromosome 1q gain and tenascin-C expression are candidate markers to define different risk groups in pediatric posterior fossa ependymoma.
Araki A; Chocholous M; Gojo J; Dorfer C; Czech T; Heinzl H; Dieckmann K; Ambros IM; Ambros PF; Slavc I; Haberler C
Acta Neuropathol Commun; 2016 Aug; 4(1):88. PubMed ID: 27550150
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of chromosome 1q gain in intracranial ependymomas.
Rajeshwari M; Sharma MC; Kakkar A; Nambirajan A; Suri V; Sarkar C; Singh M; Saran RK; Gupta RK
J Neurooncol; 2016 Apr; 127(2):271-8. PubMed ID: 26725097
[TBL] [Abstract][Full Text] [Related]
7. Epidermal growth factor receptor and caveolin-1 coexpression identifies adult supratentorial ependymomas with rapid unfavorable outcomes.
Senetta R; Miracco C; Lanzafame S; Chiusa L; Caltabiano R; Galia A; Stella G; Cassoni P
Neuro Oncol; 2011 Feb; 13(2):176-83. PubMed ID: 21059755
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical markers for prognosis of ependymal neoplasms.
Korshunov A; Golanov A; Timirgaz V
J Neurooncol; 2002 Jul; 58(3):255-70. PubMed ID: 12187959
[TBL] [Abstract][Full Text] [Related]
9. Predictors of outcome in an AIEOP series of childhood ependymomas: a multifactorial analysis.
Modena P; Buttarelli FR; Miceli R; Piccinin E; Baldi C; Antonelli M; Morra I; Lauriola L; Di Rocco C; Garrè ML; Sardi I; Genitori L; Maestro R; Gandola L; Facchinetti F; Collini P; Sozzi G; Giangaspero F; Massimino M
Neuro Oncol; 2012 Nov; 14(11):1346-56. PubMed ID: 23076205
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical markers for intracranial ependymoma recurrence. An analysis of 88 cases.
Korshunov A; Golanov A; Timirgaz V
J Neurol Sci; 2000 Aug; 177(1):72-82. PubMed ID: 10967185
[TBL] [Abstract][Full Text] [Related]
11. Infratentorial ependymomas: prognostic factors and outcome analysis in a multi-center retrospective series of 106 adult patients.
Guyotat J; Metellus P; Giorgi R; Barrie M; Jouvet A; Fevre-Montange M; Chinot O; Durand A; Figarella-Branger D
Acta Neurochir (Wien); 2009 Aug; 151(8):947-60. PubMed ID: 19499166
[TBL] [Abstract][Full Text] [Related]
12. Treatment results in patients with intracranial ependymomas.
Boström A; Boström J; Hartmann W; Pietsch T; Feuss M; von Lehe M; Simon M
Cent Eur Neurosurg; 2011 Aug; 72(3):127-32. PubMed ID: 21630189
[TBL] [Abstract][Full Text] [Related]
13. The histologic grade is a main prognostic factor for patients with intracranial ependymomas treated in the microneurosurgical era: an analysis of 258 patients.
Korshunov A; Golanov A; Sycheva R; Timirgaz V
Cancer; 2004 Mar; 100(6):1230-7. PubMed ID: 15022291
[TBL] [Abstract][Full Text] [Related]
14. Prognostic factors in intracranial ependymomas in children.
Figarella-Branger D; Civatte M; Bouvier-Labit C; Gouvernet J; Gambarelli D; Gentet JC; Lena G; Choux M; Pellissier JF
J Neurosurg; 2000 Oct; 93(4):605-13. PubMed ID: 11014538
[TBL] [Abstract][Full Text] [Related]
15. EZH2 expression is a prognostic factor in childhood intracranial ependymoma: a Canadian Pediatric Brain Tumor Consortium study.
Li AM; Dunham C; Tabori U; Carret AS; McNeely PD; Johnston D; Lafay-Cousin L; Wilson B; Eisenstat DD; Jabado N; Zelcer S; Silva M; Scheinemann K; Fryer C; Hendson G; Fotovati A; Hawkins C; Yip S; Dunn SE; Hukin J
Cancer; 2015 May; 121(9):1499-507. PubMed ID: 25586788
[TBL] [Abstract][Full Text] [Related]
16. Intracranial ependymoma: factors affecting outcome.
Massimino M; Buttarelli FR; Antonelli M; Gandola L; Modena P; Giangaspero F
Future Oncol; 2009 Mar; 5(2):207-16. PubMed ID: 19284379
[TBL] [Abstract][Full Text] [Related]
17. Correlation of bcl-2, p53, and MIB-1 expression with ependymoma grade and subtype.
Rushing EJ; Brown DF; Hladik CL; Risser RC; Mickey BE; White CL
Mod Pathol; 1998 May; 11(5):464-70. PubMed ID: 9619600
[TBL] [Abstract][Full Text] [Related]
18. Nestin expression identifies ependymoma patients with poor outcome.
Milde T; Hielscher T; Witt H; Kool M; Mack SC; Deubzer HE; Oehme I; Lodrini M; Benner A; Taylor MD; von Deimling A; Kulozik AE; Pfister SM; Witt O; Korshunov A
Brain Pathol; 2012 Nov; 22(6):848-60. PubMed ID: 22568867
[TBL] [Abstract][Full Text] [Related]
19. Prognostic relevance of localization and grading in intracranial ependymomas of childhood.
Ernestus RI; Schröder R; Stützer H; Klug N
Childs Nerv Syst; 1996 Sep; 12(9):522-6. PubMed ID: 8906366
[TBL] [Abstract][Full Text] [Related]
20. Identification of relevant prognostic histopathologic features in 69 intracranial ependymomas, excluding myxopapillary ependymomas and subependymomas.
Kurt E; Zheng PP; Hop WC; van der Weiden M; Bol M; van den Bent MJ; Avezaat CJ; Kros JM
Cancer; 2006 Jan; 106(2):388-95. PubMed ID: 16342252
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
